WHWK News
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC...
PR Newswire
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors PR Newswire MORRISTOWN, N.J., Sept. 10, 2026 Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical...
PR Newswire
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences Whitehawk Therapeutics to Participate in Upcoming Investor Conferences PR Newswire MORRISTOWN, N.J., Sept. 2, 2026 MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc.(Nasdaq: WHWK), a clinical-stage...
PR Newswire
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights PR Newswire MORRISTOWN, N.J., Aug. 6, 2026 Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1...
PR Newswire
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (Whitehawk, Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite platform...
Business Wire
Whitehawk Therapeutics Presents RealWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics Presents RealWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 Whitehawk Therapeutics Presents RealWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC...
PR Newswire
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference PR Newswire MORRISTOWN, N.J., May 28, 2026 MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc.(Nasdaq...
PR Newswire